Searched for
IXEMPRA
Dr Reddy’s Labs Q4 Preview: PAT may jump up to 12% YoY, revenue to rise up to 18% on generics business doseDr Reddy’s Q4FY25 net profit is expected to grow 1.3–12% YoY, with revenues likely rising 13–18% to ₹7,981–8,424 crore, according to broker...- Bristol-Myers sues Dr Reddy's Laboratories for patent infringement in USBristol-Myers Squibb Company has filed patent infringement case against Dr Reddy's Laboratories over the cancer drug Ixempra.
- Ten stocks in focus in Friday morning tradeIndian shares are expected to trade in a range. Here is a list of ten stocks that are likely to be in action in morning trade today.
- Load More